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Reply to the Editor:
We are gratified by Dr Anderson’s solid
endorsement of our editorial, helping to
clarify this rather confused and confusing
situation surrounding the use of the word
“actual” in the assessment of intrinsic valve
performances. We fully agree with him re-
garding the importance of the concept of
competing risks environment. His propos-
als on reporting long-term experiences with
replacement heart valves are excellent, and
we recommend that future authors follow
his advice.
The letter by Grunkemeier, Takken-
berg, and Jamieson incorrectly summarizes
in its first paragraph the content of our
editorial and therefore adds unnecessary
confusion. Dr Bodnar was probably the
first to introduce competing risks to cardiac
surgery; Dr Blackstone and colleagues
have used competing risks analyses exten-
sively in multiple settings of adult and,
particularly, congenital heart disease, and
both will continue to do so to answer ques-
tions that methodology was designed to
answer. The method is not the problem!
The problem is its inappropriate use in an-
swering questions related to intrinsic prop-
erties of heart valve substitutes, such as
comparative durability. From its beginning,
our editorial was clear about the specific,
focused context of our remarks. Rather
than restate the entire editorial to make 1
point clear, perhaps an analogy would be
helpful.
Pretend we wish to compare durability
(tread life) of 3 brands of tire. (We under-
stand that, just like structural valve deteri-
oration [SVD], this is a continuous process
and not an event; for simplicity, however,
we will estimate durability by the time to
change tires because of excessive tread
wear, just as we may estimate SVD by time
to valve replacement.) Likely there are spe-
cific risk factors for tire durability, but let
us imagine that miles traveled is the stron-
gest (just as young age is the strongest
correlate of SVD). Now, let us say that our
study of tire durability for brand A is dom-
inated by a fleet of cars operated by trav-
eling salespersons, study of brand B by
commuters living within 5 miles of work,
and study of brand C by mothers with
children involved in many after-school ac-
tivities. After a stated period, most sales-
persons have had to change tires, a number
of mothers have, but few short-distance
commuters have. Should we conclude that
A and C tires wear out too fast, and we
should switch to brand B? If we instead
compare the tires in a distance-specific
fashion using time-to-event (actuarially
based) analysis methods, we would be get-
ting closer to a fair comparison of brands
A, B, and C by isolating tire properties
from the driving specifics of their owners.
In the case of SVD, the only universally
found risk factor is age of patient at im-
plant, so age-specific durability provides a
reasonable comparison of bioprosthetic de-
vice durability. As with the tires, estimates
of durability are properly made by time-to-
event-type analyses.
You may then ask: What tire should we
recommend for the driving habits of a
given person? The answer may well de-
pend on how long different people intend
to keep their cars. A person who leases a
new car every 3 years no matter how little
he or she drives may never need to change
tires. Trading in a car, like death of a pa-
tient, is a competing risk. For someone who
drives little, there is no reason to pay a
premium for a tire of superior durability if
at trade-in there is unlikely to be much
tread wear! However, it is important to
understand that the car-trading habits of
owners do not themselves affect intrinsic
properties of the tires. So, interesting as
competing risks analysis is for answering
some questions such as those posed, for
simply comparing intrinsic durability of
tires, these trading habits are extraneous
and should not be allowed to confound the
comparison.
Choice of a prosthesis for a given pa-
tient, like choice of a tire, may well depend
on a number of factors, such as the pa-
tient’s expected longevity, which itself has
many correlations that are unrelated to in-
trinsic properties of the device. These are
appropriately evaluated by competing risks
analyses. However, longevity of the per-
son, like car-trading habits, is a far more
complex matter than the intrinsic properties
of the prostheses. Estimates of whether or
not a patient will live to experience SVD of
their prosthesis will be different for every
patient, despite the prosthesis retaining its
unchanged intrinsic durability.
It is important to recognize that in both
time-to-event and competing risks meth-
ods, time to SVD and time to death are
assumed to be completely independent of
one another. Thus, the fundamental “actu-
arial” calculation for each component of a
competing risks analysis can be performed
independently of one another, after which a
mathematical combination is made. Thus,
actuarial estimates are fundamental and un-
changing, whereas competing risk esti-
mates will vary, depending on what set of
events is considered competing or ignored.
(You may protest that it is irrational to
think there is no linkage between SVD and
death, and you are probably right. How-
ever, that is the assumption that both “ac-
tuarial” and competing risks methods as-
sume. Methods for dealing with linked
events, called methods for “informative
censoring,” are still not well developed.)
In conclusion, we suggest that Drs
Grunkemeier, Takkenberg, Jamieson, and
Miller need to realize the magnitude of the
mistake they make. Actuarial analysis and
cumulative incidence assessment are not
competing but complementary methods.
One is apple, the other orange, and oranges
should not be blamed for not being apples.
The question is not which is better—the
question is which should be used for what
purpose. Cumulative incidence cannot be
used to assess let alone compare intrinsic
valve properties. We were not advocating
that articles employing competing risks
analysis appropriately be “banned” from
our journals but that research focused on
long-term intrinsic performance of replace-
ment heart valves and their comparison not
be published with inappropriate analyses of
competing risks.
Endre Bodnar, MDa
Eugene H. Blackstone, MDb
Editor in Chief a
The Journal of Heart Valve Disease
Northwood, UK
Cleveland Clinicb
Cleveland, Ohio
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Reporting “actual freedom” should
not be banned
To the Editor:
The life of a bioprosthetic heart valve usu-
ally ends as a result of structural valve
deterioration (SVD) or death of the patient.
In this competing risks situation, the prob-
ability of SVD is estimated by the cumu-
lative incidence function, sometimes re-
ferred to as “actual” analysis.
The editorial by Bodnar and Blackstone
published in the January 2006 issue of the
Journal1 criticized this method and recom-
mended its prohibition. Specifically,
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Bodnar and Blackstone object to: (1) ter-
minology: using the name “actual” instead
of “cumulative incidence”; (2) presenta-
tion: plotting its complement and calling it
“actual freedom”; and (3) comparison: us-
ing this statistic instead of the Kaplan–
Meier (KM) method to compare valve per-
formance. We disagree with Bodnar and
Blackstone on all 3 points.
Regarding the first point, terminology,
Bodnar and Blackstone state: “We should
stop using the term ‘actual freedom.’ . . .
There is no reason to abandon the expres-
sion ‘cumulative incidence.’” Statisticians
use several names for this method, includ-
ing “cumulative incidence,” “crude proba-
bility,” “crude incidence,” “cause-specific
failure probability,” “absolute cause-specific
risk,” and “subdistribution function.” “Ac-
tual” is just a shortcut name, like saying
“Ross”—not a medical term—instead of
“pulmonary autograft” or “linearized rate”—
not a statistical term—instead of “the con-
stant hazard rate of an exponential distri-
bution.”
Bodnar and Blackstone also state: “Syn-
onyms of ‘actual’ are current, eventual, and
real, and the implication of its use is that it
is more real than the actuarial estimate.”
That is exactly the point; the term “actual”
is appropriate because it is “more real” than
the KM actuarial estimate for the individ-
ual patient’s perspective because it esti-
mates the percentage of patients who will
“actually” experience an event. If one has a
strong emotional aversion to the use of the
term “actual,” then the statistical terms
“subdistribution function” instead of “ac-
tual failure” and “subsurvival function” in-
stead of “actual freedom”2 can be substi-
tuted.
Regarding the second point, presenta-
tion, Bodnar and Blackstone state: “Other
authors . . . displayed graphically the com-
plement of cumulative incidence, which
normally rises from zero to a certain posi-
tive value, so that the new curve declined
from 100% to a certain value.” Although
the probability of having an event is the
more direct concept, its complement—the
probability of being event-free—contains
the same information and is usually pre-
ferred in survival analysis and complication-
free analysis.
In reference to the third point, compar-
ison, Bodnar and Blackstone state: “Cumu-
lative incidence . . . must not be used to
define or compare valve performance. This
should be done using actuarial [KM]
methods.” The first two issues are really a
matter of taste, but this one is a matter of
substance and statistical correctness. The
subdistribution and subsurvival functions
estimate the probability of having, or not
having, respectively, SVD in the presence
of the competing risk of death. As such, it
would not be fair to use them to compare,
say, valve A from a series with a high death
rate to valve B from a series with a low
death rate. If the death rates in 2 series were
similar, however, then the comparison of
SVD subdistribution or subsurvival func-
tions would be appropriate.3 But this same
caveat applies to KM actuarial estimates.
Comparing high SVD rates with valve X in
a younger population to low SVD rates
with valve Y in an older population would
not be correct, as the difference could be
due to patient age and other patient-related
factors alone. To make a fair comparison of
KM curves, the patient groups should also
be similar. But there also is a deeper, tech-
nical issue involved here. The subdistribu-
tion function gives a proper probability of
experiencing SVD; the KM estimate does
not.
Bodnar and Blackstone also state: “We
assume that patients who die before a non-
fatal event occurs were just as likely, while
they were alive, as anybody else to have
experienced that event, even though they
didn’t. Now, that sounds more sensible,
doesn’t it?” That is true, if indeed the
events of death and SVD are independent.
It may sound sensible, but it cannot be
demonstrated using competing risks data,4
and for this reason the KM curve resulting
from this assumption has dubious value. It
has been widely criticized as “an incorrect
use of the Kaplan–Meier method,”3 “a
meaningless quantity,”5 “irrelevant,”6 and
“inappropriate for estimation purposes in
the presence of competing risks, while the
cumulative incidence is appropriate.”7 That
is the statistical argument.8 Then there is
the clinical issue: The KM curve gives the
probability of SVD in the counterfactual
(or artificial) situation where death has
been eliminated. This, of course, will never
happen.
Bodnar and Blackstone conclude that
“the Journal will no longer publish ‘actual
freedom’ results in articles reporting long-
term performance of replacement valves.”
Although this prohibition was stated to
only apply to the reporting of long-term
performance of heart valves, this method
has other valuable uses in cardiothoracic
clinical research. Examples include the
analysis of nonfatal complications such as
aortic reoperation or stroke after surgical
repair of aortic dissection, reintervention
after thoracic aortic stent grafting, recur-
rent obstruction after esophagectomy, com-
plications after lung volume reduction op-
erations, and transplant graft disease in
cardiac allograft recipients. Presumably,
these other clinical applications are not af-
fected by the proposed prohibition. In light
of the above, we argue that the use of
“actual freedom” for reporting heart valve
complications or those following other car-
diothoracic interventions should not be
banned from The Journal of Thoracic and
Cardiovascular Surgery.
Gary L. Grunkemeier, PhDa
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Atrial fibrillation surgery: Is it time
to draw specific recommendations?
To the Editor:
We read with interest the article by Stulak
and colleagues1 evidencing the limits of
radiofrequency (RF) ablation compared
with those of the maze technique. The re-
production by RF of the lesion pattern fea-
tured in the maze operation aims to obtain
comparable results with shorter ischemic
times and reduced incision-related bleeding
risks. In fact, the results reported by the
authors cast a shadow on this assumption;
freedom from atrial fibrillation (AF) ap-
pears less satisfactory in patients treated
with ablation compared with that seen in
patients undergoing the classical maze op-
eration, both at hospital discharge and at a
median 8-month follow-up.1
The RF-based technique addresses the
same atrial lesion pattern as that of the
maze operation; subsequently, the different
outcome of the treated patients is likely to
be related to the efficacy of RF in terms of
realization of transmural lesions. The pur-
pose of RF ablation (ie, “to create full Cox
maze lesions”)1 is challenged.
The creation of transmural lesions is the
aim of ablative surgery and should be con-
sidered a “must,” ensuring procedural ef-
fectiveness. Unfortunately, intraoperative
confirmations that this goal has been
achieved are not available with the current
methodologies, leaving a question mark on
this issue, which is recalled by the results
of Stulak and colleagues.1
Nevertheless, the widespread adoption
of other-than-maze techniques (mostly
based on the topical application of various
energy sources to provoke conduction
blocks) is a measure of how uncomfortable
cardiac surgeons generally are with the
maze operation. It also explains why the
maze operation is adopted in few institu-
tions of excellence and performed in se-
lected patients instead of being a standard-
ized and accepted procedure.
In fact, in daily practice cardiac sur-
geons are favoring less-invasive, more eas-
ily reproducible, and “softer” approaches,
whose technology is in continuous evolu-
tion and whose efficacy is currently under
evaluation.
The absence of guidelines or consensus
statements, specifically those focusing on
AF surgery, has been underlined by oth-
ers.2,3 We believe that the extensive infor-
mation gained from the clinical application
of both the maze operation (since the early
1990s) and energy-based ablative surgery
(since the late 1990s) would allow the car-
diovascular community to draw recom-
mendations indicating to surgeons when
and how to proceed with AF surgery in
patients undergoing cardiac operations. We
are convinced that such recommendations
would be fundamental to orientate both the
cardiac surgeons in their daily practice and
the related research in its evolution.
Francesca di Marco, PhD, MD
Gino Gerosa, MD
Department of Cardiological, Thoracic, and
Vascular Sciences
Padua University Medical School
Division of Cardiac Surgery
Padova, Italy
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Reply to the Editor:
We agree with Drs di Marco and Gerosa
that it is time to synthesize the large
amount of data on surgical treatment of
atrial fibrillation (AF), conflicting as it
might be, and formulate guidelines for cli-
nicians. Fortunately, 2 recent publications
address this need. The Society of Thoracic
Surgeons Workforce on Evidence-based
Surgery has recently published “Guidelines
for reporting data and outcomes for the
surgical treatment of atrial fibrillation.”1
This group proposes standard descriptions
of preoperative AF, of the surgical proce-
dure, and of the lesion set performed. Fur-
thermore, the guidelines propose uniform
reporting of postoperative protocols, follow-
up methodologies, and outcome rhythm.
A second publication by the Heart
Rhythm Society Task Force on Catheter
and Surgical Ablation of Atrial Fibrillation
suggests the following indications for sur-
gical treatment of AF: (1) symptomatic pa-
tients with AF undergoing other cardiac
surgical procedures; (2) selected asymp-
tomatic patients with AF undergoing car-
diac surgery in whom the ablation can be
performed with minimal risk; and (3)
symptomatic patients with AF who prefer a
surgical approach, have experienced 1 or
more failed attempts at catheter ablation, or
are not candidates for catheter ablation.2
Although surgical intervention for AF
has been performed for 2 decades, prospec-
tive multicenter clinical trials are still
needed to define the relative safely and
efficacy of various surgical tools and tech-
niques. In addition, surgeons should use
consistent definitions of procedural success
and follow-up methodology to compare the
success of various surgical methods, as
well as outcomes of surgical intervention,
catheter ablation, and medical treatment.
John Stulak, MD
Hartzell V. Schaff, MD
Department of Cardiovascular Surgery
Mayo Clinic College of Medicine
Rochester, Minn
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